After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Portfolio Pulse from
Sage Therapeutics announced disappointing results from its Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) for cognitive impairment in Huntington's Disease patients. This follows a previous failure in an Alzheimer's study.
November 20, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics' dalzanemdor (SAGE-718) failed in a Phase 2 study for Huntington's Disease, following a previous Alzheimer's study failure. This could negatively impact investor confidence and stock price.
The failure of dalzanemdor in a second study, especially after a previous Alzheimer's study failure, is likely to decrease investor confidence in Sage Therapeutics' pipeline, potentially leading to a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100